AL
BBH icon

Aspiriant LLC’s VanEck Biotech ETF BBH Stock Holding History

Aspiriant LLC’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$629K Sell
3,347
-240
-7% -$46.2K 0.02% 194
2025
Q4 		$679K Sell
3,587
-140
-4% -$25.9K 0.02% 188
2025
Q3 		$618K Hold
3,727
– – 0.02% 185
2025
Q2 		$571K Sell
3,727
-510
-12% -$76K 0.02% 187
2025
Q1 		$667K Sell
4,237
-96
-2% -$15.6K 0.02% 166
2024
Q4 		$680K Hold
4,333
– – 0.02% 170
2024
Q3 		$769K Hold
4,333
– – 0.03% 164
2024
Q2 		$730K Sell
4,333
-75
-2% -$12.3K 0.03% 167
2024
Q1 		$733K Sell
4,408
-2,955
-40% -$489K 0.03% 164
2023
Q4 		$1.22M Sell
7,363
-40
-0.5% -$6.16K 0.05% 128
2023
Q3 		$1.15M Hold
7,403
– – 0.06% 121
2023
Q2 		$1.16M Sell
7,403
-180
-2% -$28.8K 0.06% 122
2023
Q1 		$1.23M Hold
7,583
– – 0.06% 115
2022
Q4 		$1.21M Buy
7,583
+2,955
+64% +$468K 0.06% 115
2022
Q3 		$656K Sell
4,628
-24
-0.5% -$3.63K 0.03% 151
2022
Q2 		$676K Sell
4,652
-70
-1% -$10.4K 0.03% 145
2022
Q1 		$765K Sell
4,722
-192
-4% -$31.1K 0.04% 146
2021
Q4 		$932K Buy
4,914
+674
+16% +$130K 0.05% 143
2021
Q3 		$854K Sell
4,240
-30
-0.7% -$6.3K 0.05% 126
2021
Q2 		$859K Buy
4,270
+80
+2% +$14.9K 0.05% 122
2021
Q1 		$733K Sell
4,190
-163
-4% -$29.5K 0.05% 125
2020
Q4 		$740K Sell
4,353
-235
-5% -$38.7K 0.05% 125
2020
Q3 		$743K Sell
4,588
-69
-1% -$11.2K 0.06% 125
2020
Q2 		$762K Sell
4,657
-615
-12% -$93.5K 0.07% 103
2020
Q1 		$673K Sell
5,272
-892
-14% -$120K 0.07% 105
2019
Q4 		$861K Sell
6,164
-485
-7% -$63.7K 0.08% 102
2019
Q3 		$785K Sell
6,649
-1,111
-14% -$138K 0.07% 119
2019
Q2 		$1M Sell
7,760
-754
-9% -$93K 0.08% 110
2019
Q1 		$1.09M Sell
8,514
-929
-10% -$117K 0.09% 103
2018
Q4 		$1.04M Sell
9,443
-749
-7% -$90.5K 0.08% 103
2018
Q3 		$1.38M Sell
10,192
-435
-4% -$56.6K 0.12% 95
2018
Q2 		$1.27M Sell
10,627
-773
-7% -$91.1K 0.11% 97
2018
Q1 		$1.37M Buy
+11,400
New +$1.43M 0.12% 87
2017
Q4 		– Sell
-15,903
Closed -$2.13M – 91
2017
Q3 		$2.13M Sell
15,903
-3,605
-18% -$469K 0.18% 73
2017
Q2 		$2.45M Buy
+19,508
New +$2.35M 0.21% 68
2017
Q1 		– Sell
-23,280
Closed -$2.5M – 214
2016
Q4 		$2.5M Sell
23,280
-285
-1% -$31K 0.23% 66
2016
Q3 		$2.71M Sell
23,565
-1,016
-4% -$116K 0.27% 54
2016
Q2 		$3.31M Sell
24,581
-910
-4% -$97K 0.31% 56
2016
Q1 		$2.64M Buy
+25,491
New +$2.66M 0.25% 58

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

Aspiriant LLC's BBH Position: Q1 2026 in Review

Aspiriant LLC reduced its VanEck Biotech ETF (BBH) stake by 6.7% in Q1 2026, selling an estimated $46.2K and leaving 3,347 shares worth $629K. The position accounts for 0.02% of the portfolio, ranked #194.

Aspiriant LLC first reported a position in BBH in Q1 2016 and has held it in 39 quarters since. The position peaked at $3.31M in Q2 2016. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Aspiriant LLC held 3,347 shares of VanEck Biotech ETF worth $629K as of Q1 2026.
  • Aspiriant LLC sold 240 VanEck Biotech ETF shares in Q1 2026, an estimated $46.2K.
  • VanEck Biotech ETF made up 0.02% of Aspiriant LLC's portfolio in Q1 2026, its #194 holding.
  • Aspiriant LLC first reported a position in VanEck Biotech ETF in Q1 2016 and has held it in 39 quarters since.
  • Aspiriant LLC's VanEck Biotech ETF position peaked at $3.31M in Q2 2016.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.